A sudden worsening of symptoms in a patient with chronic obstructive pulmonary disease often signals an exacerbation, a clinical turning point that requires swift and structured management. These episodes are usually triggered by respiratory infections, air pollution, or poor adherence to therapy, and they present with increased breathlessness, cough, and changes in sputum volume or character. Because exacerbations accelerate lung function decline and raise the risk of hospitalization, early recognition is critical.
COPD exacerbation management begins with rapid assessment of severity, using arterial blood gases, pulse oximetry, and clinical evaluation. Oxygen therapy is provided carefully to maintain adequate saturation without causing hypercapnia. Short-acting bronchodilators, often administered via nebulization, form the foundation of acute treatment, frequently combined with systemic corticosteroids to reduce airway inflammation. When bacterial infection is suspected, antibiotics are prescribed to shorten recovery and prevent complications. In moderate to severe cases, non-invasive ventilation plays a pivotal role in reducing the need for intubation.
Equally important is post-exacerbation care. Patients benefit from medication review, inhaler technique reinforcement, and enrollment in pulmonary rehabilitation programs. Vaccinations, smoking cessation, and long-acting maintenance therapies help prevent future flare-ups. Current research is exploring biomarkers to predict exacerbations and novel anti-inflammatory agents that may limit recurrence. COPD exacerbation management, therefore, is not limited to acute intervention but extends into long-term strategies aimed at stabilizing disease trajectory and reducing the cycle of recurrent flare-ups.
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Susceptibility to SARS-CoV-2 infection and nasal air conditioning ability
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Comparative evaluation of DECAF and BAP 65 scores in predicting outcomes of COPD exacerbations among in patients at Vicente Sotto Memorial Medical Center
Allanys Joy Q Pino, Vicente Sotto Memorial Medical Center, Philippines
Title :
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States
Title : Personalized and precision Medicine (PPM) as a unique healthcare model through biodesign driven and inspired biotech, translational applications and pulmonology related marketing to secure the human healthcare, wellness and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation